Manufacturing / Pharmaceutical Preparations
Akebia Therapeutics, Inc.
AKBA
$0.82
+$0.01 (+0.73%)
Price as of Oct 9, 2026 18:38 UTC
250 M
Market Cap (Micro Cap)
Oct 29
Next Earnings
Technical Signals
as of Oct 7
Bearish
0 of 7
Trend
- Above 20-day average $0.91
- Above 50-day average $0.97
- Above 200-day average $1.32 · -34.2%
- Moving averages stacked Not aligned
Momentum
- Golden cross (50/200) —
- Momentum cross (20/50) Down · 41d ago
Volume
- Below-average volume 1.4x avg
Price & Trend
Daily candles with EMA 20, SMA 50. Drag to zoom.
Options Heat Map
Delta-risk grid for AKBA options across strikes and expirations. Hover any cell for full Greeks.
Loading option chain data...
Insider Trades
1 buys
19 sells
| Date | Insider | Title | Type | Shares | Value | Since Trade |
|---|---|---|---|---|---|---|
| Aug 06, 2026 | Butler John P. | Exercise | 350,000 | $0 | -14.7% | |
| Aug 06, 2026 | Butler John P. | Exercise | 350,000 | $220,500 | +28.6% | |
| Jun 29, 2026 | Ostrowski Erik | Sell | 56,019 | $62,181 | -27.0% | |
| Jun 17, 2026 | FRIESON RON | Grant | 53,600 | $0 | -20.6% | |
| Jun 17, 2026 | FRIESON RON | Grant | 35,700 | $0 | -20.6% | |
| Jun 17, 2026 | ZUMWALT LEANNE M | Grant | 53,600 | $0 | -20.6% | |
| Jun 17, 2026 | ZUMWALT LEANNE M | Grant | 35,700 | $0 | -20.6% | |
| Jun 17, 2026 | Wolf Myles | Grant | 53,600 | $0 | -20.6% | |
| Jun 17, 2026 | ROGERS MICHAEL W | Grant | 53,600 | $0 | -20.6% | |
| Jun 17, 2026 | ADAMS ADRIAN | Grant | 53,600 | $0 | -20.6% |
Earnings History
| Date | Quarter | EPS Est. | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Aug 05, 2026 | Q2 2026 | -$0.04 | |||
| Jul 30, 2026 | Q2 2026 | -$0.04 | |||
| Mar 31, 2026 | Q1 2026 | -$0.03 | -$0.03 | -4.9% | Miss |
| Dec 31, 2025 | Q4 2025 | -$0.03 | -$0.05 | -96.1% | Miss |
| Sep 30, 2025 | Q3 2025 | -$0.02 | $0.00 | +100.0% | Beat |
| Jun 30, 2025 | Q2 2025 | -$0.02 | $0.00 | +100.0% | Beat |
| Mar 31, 2025 | Q1 2025 | -$0.05 | $0.03 | +165.4% | Beat |
Track AKBA with ThetaPal
Get insider trade alerts, AI portfolio analysis, and options roll recommendations for AKBA and your entire portfolio.